Trial Profile
A study analyzing serum glycoproteomic signatures and association with survival in patients with bone and soft tissue sarcoma treated with immune-checkpoint inhibitor therapy
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 14 Jul 2022
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary) ; Tremelimumab (Primary)
- Indications Bone cancer; Soft tissue sarcoma; Solid tumours
- Focus Biomarker; Therapeutic Use
- 14 Jul 2022 New trial record
- 07 Jun 2022 Results presented at the 58th Annual Meeting of the American Society of Clinical Oncology